UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 373

Sortiert nach

Adaptive-Optimal Design in PET Occupancy Studies

Clinical pharmacology and therapeutics, 2010-05, Vol.87 (5), p.563-571

2010

Volltextzugriff (PDF)

Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials

ESMO open, 2021-08, Vol.6 (4), p.100171-100171, Article 100171

2021

Volltextzugriff (PDF)

A normal electro-oculography in a family affected by best disease with a novel spontaneous mutation of the BEST1 gene

British journal of ophthalmology, 2008-11, Vol.92 (11), p.1467-1470

2008

Volltextzugriff (PDF)

1826P Lutetium-177-PSMA in pre- and post-taxane mCRPC setting: Results from a phase II clinical trial

Annals of oncology, 2023-10, Vol.34, p.S989-S989

2023

Volltextzugriff (PDF)

Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients

European journal of nuclear medicine and molecular imaging, 2021, Vol.48 (1), p.87-94

2021

Volltextzugriff (PDF)

Care Pathway of RPE65-Related Inherited Retinal Disorders from Early Symptoms to Genetic Counseling: A Multicenter Narrative Medicine Project in Italy

Clinical ophthalmology (Auckland, N.Z.), 2021-01, Vol.15, p.4591-4605

2021

Volltextzugriff (PDF)

Evaluation of imaging, clinical and pathological factors associated with 2-year biochemical recurrence in surgical patients with intermediate- to high-risk prostate cancer: A focus on 68Ga-PSMA PET and pelvic 3Tesla mpMRI

European urology open science (Online), 2023-10, Vol.56, p.S61

2023

Volltextzugriff (PDF)

UP40 - Evaluation of imaging, clinical and pathological factors associated with 2-year biochemical recurrence in surgical patients with intermediate- to high-risk prostate cancer: A focus on 68Ga-PSMA PET and pelvic 3Tesla mpMRI

European urology open science (Online), 2023-10, Vol.56, p.S61-S61

2023

Volltextzugriff (PDF)

PSMA PET/CT and radiotherapy in prostate cancer: a winning team

Clinical and translational imaging : reviews in nuclear medicine and molecular imaging, 2022, Vol.10 (2), p.163-172

2022

Volltextzugriff (PDF)

Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry

Physica medica, 2021-12, Vol.92, p.S89

2021

Volltextzugriff (PDF)

OL47 - Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry

Physica medica, 2021-12, Vol.92, p.S23-S24

2021

Volltextzugriff (PDF)

OD71 - Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry

Physica medica, 2021-12, Vol.92, p.S89-S89

2021

Volltextzugriff (PDF)

Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry

Physica medica, 2021-12, Vol.92, p.S23-S24

2021

Volltextzugriff (PDF)

Clinical phenotype of an Italian family with a new mutation in the PRPF8 gene

European journal of ophthalmology, 2006-09, Vol.16 (5), p.779-781

2006

Volltextzugriff (PDF)

Dietary antioxidants as potential pharmacological agents for ischemic stroke

Current medicinal chemistry, 2008-05, Vol.15 (12), p.1236

2008

Volltextzugriff (PDF)

UP43 - Therapy with 177Lu-PSMA-617 in advanced mCRPC patients: Results of the phase 2 prospective trial IRST-185.03 (EUDRACT: 2016-002732-32)

European urology open science (Online), 2023-10, Vol.56, p.S64-S64

2023

Volltextzugriff (PDF)

Therapy with 177Lu-PSMA-617 in advanced mCRPC patients: Results of the phase 2 prospective trial IRST-185.03 (EUDRACT: 2016-002732-32)

European urology open science (Online), 2023-10, Vol.56, p.S64

2023

Volltextzugriff (PDF)

Recombinant granulocyte colony-stimulating factors (rG-CSFs) in the management of NEUtropenia induced by anthracyclines and ifosfamide in patients with soft tissue SARcomas (NEUSAR)

Annals of oncology, 2016-09, Vol.27, p.iv99

2016

Volltextzugriff (PDF)

Clinical value of negative 68 Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients

European journal of nuclear medicine and molecular imaging, 2021-01, Vol.48 (1), p.87

2021

Volltextzugriff (PDF)

100. 177Lu-PSMA molecular radiotherapy: Strategy to reduce organ at risks uptake

Physica medica, 2018-12, Vol.56, p.123-124

2018

Volltextzugriff (PDF)

Response of brain metastases from non-small cell lung cancer to first-line pemetrexed-based chemotherapy: A single-center experience

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e18052-e18052

2011

Volltextzugriff (PDF)

THE TARGET SIGN: A Near Infrared Feature and Multimodal Imaging in a Pluri-Ethnic Cohort with RDH5-Related Fundus Albipunctatus

Retina (Philadelphia, Pa.), 2022-07, Vol.42 (7), p.1364

2022

Volltextzugriff (PDF)

An Atypical Form of Bietti Crystalline Dystrophy

Ophthalmic genetics, 2011-06, Vol.32 (2), p.118-121

2011

Volltextzugriff (PDF)

Reproducibility of en-face Optical Coherence Tomography Imaging for Macular Atrophy Area Evaluation in Juvenile Macular Degeneration

XIV Mediterranean Conference on Medical and Biological Engineering and Computing 2016, p.250-253

Volltextzugriff (PDF)

1 P Gastrointestinal hemorrhage from ulcer: Cost-benefit of medical treatment

Digestive and liver disease, 2002-06, Vol.34, p.A138-A138

2002

Volltextzugriff (PDF)

1 – 25 von 373

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(321)
Mit Volltextzugriff
(310)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(210)
Humans
(186)
Life Sciences & Biomedicine
(181)
Female
(127)
Male
(93)
Adult
(74)
Biological And Medical Sciences
(71)
Middle Aged
(61)
Medical Sciences
(58)
Aged
(46)
Urology & Nephrology
(38)
Neurosciences & Neurology
(27)
Physical Sciences
(23)
Italy
(22)
Pregnancy
(22)
Animals
(21)
Neurosciences
(20)
Clinical Neurology
(19)
Physics Of Elementary Particles And Fields
(19)
Time Factors
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adaptive-Optimal Design in PET Occupancy Studies

Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials

A normal electro-oculography in a family affected by best disease with a novel spontaneous mutation of the BEST1 gene

1826P Lutetium-177-PSMA in pre- and post-taxane mCRPC setting: Results from a phase II clinical trial

Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients

Care Pathway of RPE65-Related Inherited Retinal Disorders from Early Symptoms to Genetic Counseling: A Multicenter Narrative Medicine Project in Italy

Evaluation of imaging, clinical and pathological factors associated with 2-year biochemical recurrence in surgical patients with intermediate- to high-risk prostate cancer: A focus on 68Ga-PSMA PET and pelvic 3Tesla mpMRI

UP40 - Evaluation of imaging, clinical and pathological factors associated with 2-year biochemical recurrence in surgical patients with intermediate- to high-risk prostate cancer: A focus on 68Ga-PSMA PET and pelvic 3Tesla mpMRI

PSMA PET/CT and radiotherapy in prostate cancer: a winning team

Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry

OL47 - Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry

OD71 - Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry

Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry

Clinical phenotype of an Italian family with a new mutation in the PRPF8 gene

Dietary antioxidants as potential pharmacological agents for ischemic stroke

UP43 - Therapy with 177Lu-PSMA-617 in advanced mCRPC patients: Results of the phase 2 prospective trial IRST-185.03 (EUDRACT: 2016-002732-32)

Therapy with 177Lu-PSMA-617 in advanced mCRPC patients: Results of the phase 2 prospective trial IRST-185.03 (EUDRACT: 2016-002732-32)

Recombinant granulocyte colony-stimulating factors (rG-CSFs) in the management of NEUtropenia induced by anthracyclines and ifosfamide in patients with soft tissue SARcomas (NEUSAR)

Clinical value of negative 68 Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients

100. 177Lu-PSMA molecular radiotherapy: Strategy to reduce organ at risks uptake

Response of brain metastases from non-small cell lung cancer to first-line pemetrexed-based chemotherapy: A single-center experience

THE TARGET SIGN: A Near Infrared Feature and Multimodal Imaging in a Pluri-Ethnic Cohort with RDH5-Related Fundus Albipunctatus

An Atypical Form of Bietti Crystalline Dystrophy

Reproducibility of en-face Optical Coherence Tomography Imaging for Macular Atrophy Area Evaluation in Juvenile Macular Degeneration

1 P Gastrointestinal hemorrhage from ulcer: Cost-benefit of medical treatment

Suchergebnisse filtern